基于[18F]FDG PET-CT影像组学特征预测非小细胞肺癌新辅助化疗免疫治疗病理完全缓解的多中心研究
该多中心研究纳入5中心185例接受新辅助化疗免疫治疗的非小细胞肺癌患者,构建基于[18F]FDG PET-CT的影像组学模型预测病理完全缓解。验证队列中PET-CT影像组学模型AUC为0.818(95%CI 0.711-0.925),优于PET影像组学模型、CT影像组学模型和最大标准摄取值。
要点
- PET-CT影像组学模型可预测非小细胞肺癌新辅助化疗免疫治疗的病理完全缓解。
- 验证队列AUC 0.818,优于单独PET、单独CT影像组学模型及最大标准摄取值。
- 高影像组学评分与抑制肿瘤增殖通路上调及抗肿瘤免疫细胞浸润相关。
核心结论
- 所提出的PET-CT影像组学模型能够预测非小细胞肺癌患者新辅助化疗免疫治疗的病理完全缓解,提示该模型可能有助于肺癌患者新辅助化疗免疫治疗的个体化。
研究设计与样本
- 多中心研究,纳入2019年1月至2022年12月5个中心接受新辅助化疗免疫治疗的185例非小细胞肺癌患者,分为训练队列和验证队列;采用最小绝对收缩和选择算子(LASSO)方法构建影像组学模型;以受试者工作特征曲线下面积(AUC)评估模型性能;并进行基因分析以揭示影像组学评分的生物学基础。
诊断标准与关键数值
- LASSO过程后筛选出9个PET-CT影像组学特征用于预测病理完全缓解;验证队列中PET-CT影像组学模型预测病理完全缓解的AUC为0.818(95%CI 0.711-0.925),优于PET影像组学模型(AUC 0.728,95%CI 0.610-0.846)、CT影像组学模型(AUC 0.732,95%CI 0.607-0.857)和最大标准摄取值(AUC 0.603,95%CI 0.473-0.733)(p < 0.05)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aims to develop and validate a radiomics model based on 18F-fluorodeoxyglucose positron emission tomography-computed tomography ([18F]FDG PET-CT) images to predict pathological complete response (pCR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: One hundred eighty-five patients receiving neoadjuvant chemoimmunotherapy for NSCLC at 5 centers from January 2019 to December 2022 were included and divided into a training cohort and a validation cohort. Radiomics models were constructed via the least absolute shrinkage and selection operator (LASSO) method. The performances of models were evaluated by the area under the receiver operating characteristic curve (AUC). In addition, genetic analyses were conducted to reveal the underlying biological basis of the radiomics score.
RESULTS: After the LASSO process, 9 PET-CT radiomics features were selected for pCR prediction. In the validation cohort, the ability of PET-CT radiomics model to predict pCR was shown to have an AUC of 0.818 (95% confidence interval [CI], 0.711, 0.925), which was better than the PET radiomics model (0.728 [95% CI, 0.610, 0.846]), CT radiomics model (0.732 [95% CI, 0.607, 0.857]), and maximum standard uptake value (0.603 [95% CI, 0.473, 0.733]) (p < 0.05). Moreover, a high radiomics score was related to the upregulation of pathways suppressing tumor proliferation and the infiltration of antitumor immune cell.
CONCLUSION: The proposed PET-CT radiomics model was capable of predicting pCR to neoadjuvant chemoimmunotherapy in NSCLC patients.
CLINICAL RELEVANCE STATEMENT: This study indicated that the generated 18F-fluorodeoxyglucose positron emission tomography-computed tomography radiomics model could predict pathological complete response to neoadjuvant chemoimmunotherapy, implying the potential of our radiomics model to personalize the neoadjuvant chemoimmunotherapy in lung cancer patients.
KEY POINTS: • Recognizing patients potentially benefiting neoadjuvant chemoimmunotherapy is critical for individualized therapy of lung cancer. • [18F]FDG PET-CT radiomics could predict pathological complete response to neoadjuvant immunotherapy in non-small cell lung cancer. • [18F]FDG PET-CT radiomics model could personalize neoadjuvant chemoimmunotherapy in lung cancer patients.
引用
- Yang M, Li X, Cai C, et al. [18F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study. Eur Radiol. 2023. PMID: 38127071. doi:10.1007/s00330-023-10503-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。